Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Finished Goods (2016 - 2018)

Vanda Pharmaceuticals' Finished Goods history spans 5 years, with the latest figure at $1.0 million for Q1 2018.

  • On a quarterly basis, Finished Goods rose 31.98% to $1.0 million in Q1 2018 year-over-year; TTM through Mar 2018 was $1.0 million, a 31.98% increase, with the full-year FY2017 number at $760000.0, changed 0.26% from a year prior.
  • Finished Goods hit $1.0 million in Q1 2018 for Vanda Pharmaceuticals, up from $760000.0 in the prior quarter.
  • Over the last five years, Finished Goods for VNDA hit a ceiling of $3.4 million in Q4 2014 and a floor of $611000.0 in Q2 2017.
  • Historically, Finished Goods has averaged $1.5 million across 5 years, with a median of $941000.0 in 2014.
  • The widest YoY moves for Finished Goods: up 181.19% in 2015, down 61.87% in 2015.
  • Tracing VNDA's Finished Goods over 5 years: stood at $3.4 million in 2014, then plummeted by 61.87% to $1.3 million in 2015, then tumbled by 41.11% to $762000.0 in 2016, then fell by 0.26% to $760000.0 in 2017, then soared by 33.03% to $1.0 million in 2018.
  • Business Quant data shows Finished Goods for VNDA at $1.0 million in Q1 2018, $760000.0 in Q4 2017, and $858000.0 in Q3 2017.